Responses

Download PDFPDF
Short report
Niflumic acid and cutaneous reactions in children
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Niflumic acid and cutaneous reactions in children: a reply

    Dear Editor,

    We saw the letter by Grigoletto and Viola [1], in response to our article [2]and we would like to reply to the specific comments that were put forward. The first remark relates to the possibility that we may have introduced a bias in the choice of the conditions that were selected as controls. The selection of the control group is always a critical aspect in the design of a case-control study. In...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Niflumic acid and cutaneous reactions: a controversial association.

    DEAR EDITOR,

    We read the Short Report by Menniti-Ippolito et al[1] with interest. Their conclusions assert that the administration of niflumic acid to paediatric patients increases the risk of mucocutaneous reactions with statistical significance, and thus it would not seem opportune to prescribe this drug given the availability of other safer analgesics and antipyretics. We believe that their results cannot ju...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Use of niflumic acid in children
    • Maurizio Bonati, Laboratory for Mother and Child Health
    • Other Contributors:
      • "Antonio Clavenna, Francesca Rocchi, Piero Impicciatore"

    Dear Editor

    The recent report of serious mucocutaneous reactions in fifteen Italian children who took niflumic acid in general practice raises concerns about the rational use of drugs in children everywhere [1]. Niflumic acid (and its beta-morpholinoethyl ester: morniflumate) is a non-steroidal anti-inflammatory drug (NSAID) that has been marketed in Italy since 1981 and also available for use in children in France a...

    Show More
    Conflict of Interest:
    None declared.